
Protagonist Therapeutics, Inc.: updates and filings
Price
$124.02
November 19, 2026Market cap $7.9B
What Ploutos Investor adds for Protagonist Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 9 fiscal years, from 2017
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 5, 2026next Feb 5, 2027
A rough estimate from when it has reported before, which has varied. The company announces the date itself.
November 2026
August 2026
May 2026
February 2026
November 2025
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 6, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Results of operationsForm8-K
- Oct 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 7, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 5, 2026FilingFormS-8 POS
- Aug 5, 2026FilingFormS-8 POS
- Aug 5, 2026FilingFormS-8 POS
- Aug 5, 2026FilingFormS-8 POS
- Aug 5, 2026FilingFormS-8 POS
- Aug 5, 2026FilingFormS-8 POS
- Aug 5, 2026FilingFormS-8 POS
- Aug 5, 2026FilingFormS-8 POS
- Aug 5, 2026FilingFormS-8 POS
- Aug 5, 2026FilingFormS-8 POS
- Aug 5, 2026FilingFormS-8 POS
- Aug 5, 2026Shares registered for employeesFormS-8
- Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 5, 2026Results of operations, Regulation FD disclosureForm8-K
- Jun 18, 2026Officer or director change, shareholder voteForm8-K
- May 12, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 5, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 5, 2026Results of operationsForm8-K
- Apr 30, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 6, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Results of operations | Document |
| Oct 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 7, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 5, 2026 | S-8 POS | Filing | Document |
| Aug 5, 2026 | S-8 POS | Filing | Document |
| Aug 5, 2026 | S-8 POS | Filing | Document |
| Aug 5, 2026 | S-8 POS | Filing | Document |
| Aug 5, 2026 | S-8 POS | Filing | Document |
| Aug 5, 2026 | S-8 POS | Filing | Document |
| Aug 5, 2026 | S-8 POS | Filing | Document |
| Aug 5, 2026 | S-8 POS | Filing | Document |
| Aug 5, 2026 | S-8 POS | Filing | Document |
| Aug 5, 2026 | S-8 POS | Filing | Document |
| Aug 5, 2026 | S-8 POS | Filing | Document |
| Aug 5, 2026 | S-8 | Shares registered for employees | Document |
| Aug 5, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 5, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Jun 18, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 12, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 5, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 5, 2026 | 8-K | Results of operations | Document |
| Apr 30, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Sep 28, 2006.
The full analysis
What do Protagonist Therapeutics's filings show?
The filings are where every one of Protagonist Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.